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Correction of acidosis in CAPD decreases whole body protein degra-
dation. Correction of acidosis in CAPD decreases protein degradation and
synthesis but has no effect on leucine oxidation. The effect of the
correction of metabolic acidosis in CRF patients treated with CAPD was
determined from the kinetics of infused L-[1-'3C}leucine. Seven CAPD
patients were studied before (acid) and after correction of acidosis
(bicarbonate) (pH: acid 7.39 0.01, bicarbonate 7.41 0.01, P = 0.005).
Leucine appearance from body protein (PS) and leucine disappearance
into body protein (PD) decreased significantly with correction of acidosis.
(PS: acid 211.7 9.8, bicarbonate 142.3 4.2 .tmol . kg . hr', P <
0.001; PD: acid 200.6 8.5, bicarbonate 132.4 3.7 j.mol . kg hr1,
P < 0.001). There was no significant change in leucine oxidation or plasma
amino acid concentrations. These results demonstrate that optimal cor-
rection of acidosis in CAPD is beneficial in terms of protein turnover.
Acidosis is a common feature of patients with chronic renal
failure (CRF) before the onset of renal replacement therapy. This
is associated with increased protein degradation and amino acid
oxidation [1, 21, and impaired glucose tolerance [3]. One of the
aims of treating CRF by continuous ambulatory peritoneal dial-
ysis (CAPD) is to correct acidosis by the inclusion of a buffer in
the dialysate. This has traditionally been lactate, although acetate
has been used and bicarbonate is currently being evaluated [4, 5].
The concentration of lactate used has varied between 35 and 40
mmol/Iiter; with the lower concentration a significant proportion
of patients remain acidotic [6]. In this study the hypothesis that
optimal correction of acidosis in CAPD will reduce protein
degradation in a manner similar to that seen in pre-dialysis
patients has been tested by measuring whole body protein degra-
dation using primed continuous infusions of the stable isotope
L-[1-13C]leucine before and after the correction of acidosis.
Methods
Subjects
Two male and five female CAPD subjects were studied (Table
1). Subjects with a history of thyroid disease or diabetes mellitus,
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and those taking corticosteroids were excluded from the study. All
patients had chronic metabolic acidosis, defined as a mean venous
tCO2 < 22 mmol/liter for at least three months prior to the study.
Written informed consent was obtained from each subject, and
the experimental protocol was approved by the joint ethics
committee of Newcastle Health Authority and the University of
Newcastle upon Tyne. All subjects were using a peritoneal dialysis
solution containing 35 mmollliter lactate.
Abbreviations
To remain consistent with recognized abbreviations in the field
of whole body protein turnover using stable isotopes, for the rest
of this paper PD will be used for protein degradation, and PS for
protein synthesis.
Isotopes
L-[1-13C]leucine (99 mole% '3C) and NaH'3C03 (99 mole%
13C) were purchased from Promochem (St. Albans, Herts, UK).
They were diluted with normal saline under sterile conditions in
the Pharmacy Manufacturing Department of the Royal Victoria
Infirmary, Newcastle upon Tyne, U.K., and were tested for
sterility and pyrogenicity.
Experimental design
The study consisted of two consecutive four-week periods,
separated by a two-week washout period. During one period,
subjects were prescribed oral sodium bicarbonate at an initial
dose of 2 g per day. They were reviewed weekly, blood pressure
and venous tCO2 were measured on each occasion. The dose of
sodium bicarbonate was adjusted to optimise correction of acido-
sis, the target venous tCO2 being 25 mmol/liter. If after two weeks
on oral sodium bicarbonate, the optimal venous tCO2 was not
achieved, the dose was increased to 3 g per day, this was necessary
for subjects 3 and 5. During the other four week period subjects
underwent their normal peritoneal dialysis without sodium bicar-
bonate. At the end of each four week period subjects underwent
a primed constant infusion of L-[1-'3C]leucine to measure leucine
kinetics. Patients were randomized to the order of treatment.
For the three days prior to the isotope infusion, subjects were
asked to keep a food diary, this was subsequently analyzed by a
renal dietician. Prior to admission to the metabolic research unit,
subjects were asked to undertake a 24 hour collection of both
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1 F 60 18.3 GN
2 M 58 20.8 APCKD
3 F 54 18.6 Unknown
4 F 60 21.4 RV
5 M 59 19.3 APCKD
6 F 20 18.7 CPN
7 F 60 18.1 GN
Abbreviations are: GN, glomerulonephritis; APCKD, adult polycystic
kidney disease; RV, renovascular disease; CPN, chronic pyelonephritis.
peritoneal effluent and urine. On admission they were weighed in
stockinged feet, and height was measured. As close as possible to
the day of infusion, whole body potassium was estimated using a
shadow shield device [7].
L-[1-13C]leucine infusion
Following an overnight fast, subjects were admitted to a meta-
bolic research laboratory. The isotope infusion was performed
with the peritoneal cavity "dry". At 8:00 a.m., a cannula (18G
Vasculon; Viggo-Spectrometer, Sweden) was placed retrogradely
in a dorsal hand vein for blood sampling. The hand was placed in
a heated chamber, maintained at 60°C, to allow sampling of
arterialized blood [8, 9]. A further cannula (18G Venflon; Viggo-
Spectrometer) was placed in a forearm vein in the contra lateral
arm for the primed constant infusion of L-[1-13C]leucine (Model
940; Harvard Apparatus, Millis, MA, USA). Both cannulas were
inserted under local anaesthetic (1% lignocaine).
Samples of blood and expired air were collected (at —30, —15,
and —1 mm before the infusion of L-[l-13C]leucine) to determine
the basal 13C enrichment of plasma a-ketoisocaproate (KIC) and
CO2. Samples were also taken for measurement of electrolytes,
plasma amino acids, glucose and intermediary metabolites.
To reduce the time required to reach isotopic equilibrium [10],
priming doses of L-[1-'3C]leucine (0.5 mg/kg) and NaH'3C03
(0.087 mg/kg) were then given, and a four hour constant infusion
of L-[1-13C]leucine (0.5 mg kg' hr1) commenced.
During the last hour of the infusion, five heparinized blood
samples were obtained at 15 minute intervals, centrifuged at 7°C,
and plasma aliquots stored at —70°C until subsequent analysis for
13C enrichment for plasma MC. At the same time points during
the last hour of the infusion, five samples of expired air were
collected at 15 minutes intervals into evacuated glass Vacutainer
tubes (Becton Dickinson, Rutherford, NJ, USA) and stored at
room temperature until analyzed for '3C enrichment of CO2.
Carbon dioxide production (VCO2) was measured at steady
state by open-circuit indirect calorimetry, using a ventilated hood
system (Deltatrac MBM-100; Datex Instrumentation). This was
measured on two occasions, at the onset of the infusion to
acclimatise subjects to the hood, and then continuously for 30
minutes immediately before the last hour of the constant infusion.
Three separate samples of arterialized blood were collected at
30-minute intervals during the last hour of the infusion for the
measurement of PCO2, P02 and pH.
Analytic methods
The trimethylsilylquinoxalinol derivative was created as de-
scribed previously [11]. Electron ionization—gas chromatography—
mass spectrometry (Finnigan 1020B quadrupole instrument) was
used to measure the ions (mass per unit charge = 232 and 233)
[12]. The 13C enrichment of CO2 in expired air was determined by
isotope ratio mass spectrometry (Finnigan Delta D instrument;
MAT, Hemel Hempstead, UK) [13].
Plasma amino acids were analyzed using a Beckman 6300
amino acid analyzer, using ion-exchange chromatography and
post column detection after reaction with ninhydrin. Blood sam-
ples for glycerol, pyruvate, acetoacetate, and /3-hydroxybutyrate
were taken in 5 ml of chilled HC1O4 (500 mM) and assayed by an
automated flurometric enzymatic method [14]. Electrolytes were
measured on a Technicon SMAC system and glucose using a
glucose oxidase electrode.
PCO2, PU2 and pH in arterialized blood were measured with a
blood gas analyzer (model 178, Corning).
NPCR and 1(1/V urea
Weekly Kt/V urea was calculated from the sum of dialytic Kdt/V
and renal Krt/V [15]. The normalized protein catabolic rate
(NPCR) was calculated according to the regression equation
derived from the data of Blumenkrantz [16]. This method assumes
that the total nitrogen losses (estimated from urea nitrogen
appearance in dialysate and urine) expressed as protein losses will
approximate dietary protein intake under steady state conditions.
Calculations
The model and calculations of leucine metabolism have been
described previously [10]. Leucine carbon flux (Q) is equal to the
sum of leucine disappearance into the body proteins (PS) plus
leucine oxidation (0) and to the sum of leucine appearance from
protein degradation (PD) plus dietary intake of leucine (I).
Therefore leucine carbon flux Q = PS + 0 = PD + I. In the
fasting state, I = 0 and therefore PD is equal to Q, thus Q0 =PS
+ 0 = PD.
Leucine carbon flux was calculated from the enrichment of KIC
by 13C, because this has been reported to give a more accurate
estimate of the intracellular enrichment of leucine [17]. Thus
leucine carbon flux in micromoles per kilogram per hour is: Q
i(EI/EKJC — 1) where i is the L-[1-'3C]leucine infusion rate, E1, the
13C enrichment of the L-[1-'3C]leucine infused, and the 13C
enrichment of plasma MC measured at isotopic equilibrium.
Leucine oxidation, calculated from the 13C02 expiration rate
and the '3C enrichment of plasma KIC, is: 0 = F'3C02 (l/E
— l/E1) x 100 where F13C02 is the rate of expired 13C02 (mol
'3C kg' hr1) calculated from the 13C enrichment of CO2 in
expired air and from VCO2.
Statistical analysis
Rates are expressed as micromoles per kilogram per hour.
Values are reported as means SE and analyzed using paired
t-tests. P < 0.05 was considered statistically significant.
Results
Body weight and blood pressure
There were no significant changes in weight or blood pressue at
the time of the infusions (weight: acid 73.4 6.5 vs. bicarbonate
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Mean sn 19.3 0.5 26.2 0.9 7.39 0.01 7.41 0.01
73.4 6.1 kg, P NS; systolic BP: acid 152 9 vs. bicarbonate
159 11 mm Hg, P = NS; diastolic BP: acid 91 4 vs.
bicarbonate 94 6 mm Hg, P = NS).
Plasma bicarbonate and pH
The pH of arterialized blood and venous tCO2 increased after
correction of acidosis (pH: acidotic 7.39 0.01 vs. bicarbonate
7.41 0.01, P = 0.005; tCO2: acidotic 19.3 0.5 vs. bicarbonate
26.2 0.9 mmol/liter, P < 0.001; Table 2).
Glucose, and intermediate metabolites
There were no significant differences in post absorptive values
of glucose and intermediary metabolites in the acidotic and
corrected states (Table 3).
Leucine kinetics
Leucine appearance from protein breakdown and leucine dis-
appearance into proteins were significantly decreased following
correction of acidosis (Table 4). There was no significant change
in leucine oxidation following correction of acidosis.
Plasma amino acids and plasma urea
There were no significant changes in the post-absorptive amino
acid levels following correction of acidosis for the majority of
amino acids (Table 5). There was a reduction in 3 methylhistidine
(acid 45 11 vs. bicarbonate 21 3 imol/liter; P < 0.05). Plasma
urea was significantly lower following the correction of acidosis
(acid 23.7 1.5 vs. bicarbonate 19.6 1.5 mmol/liter; P < 0.01).
NPCR and Kt/V urea
There were no significant changes in NPCR or weekly Kt/V
urea following correction of acidosis (Table 6).
Dietary intake
There was no significant change in protein or carbohydrate
intake following correction of acidosis (carbohydrate: acid 1198
312 vs. bicarbonate 1308 390 kcal/24 hr; protein: acid 66.6 4.9
vs. bicarbonate 74.6 6.9 g/24 hr).
Whole body potassium
There was no significant change in lean body mass as assessed
by whole body potassium measurements before and after the
correction of acidosis (acid 105.5 18.3 vs. bicarbonate 114.1
15.6 g).
Discussion
This study examined the effect on leucine kinetics of correcting
chronic metabolic acidosis in CAPD. The kinetics of a primed
constant infusion of L-[1-13C]leucine have been used as a model
of whole body protein metabolism. The results show that correc-
tion of chronic acidosis in CAPD is associated with a reduction in
PS and PD but not 0. With the exception of 3 methyl histidine
(Table 5), there was no change in plasma amino acids following
the correction of acidosis.
Other studies have suggested that protein degradation de-
creases with the correction of acidosis. Nitrogen balance improves
when the acidosis associated with CRF [18] and prolonged fasting
[19] is corrected, and L-[1-13C]leucine infusion studies have
confirmed that correcting acidosis in CRF patients not yet requir-
ing dialysis, reduces PS, PD and 0 [1]. This is the first study to
demonstrate that correction of acidosis in CAPD decreases
protein degradation.
In a previous paper by Reaich et a!, correction of acidosis in
humans with CRF decreased protein degradation [1]. In that
paper subjects had CRF, but none had been dialyzed. They were
more severely acidotic (plasma bicarbonate acid 15 1 vs.
bicarbonate 21 1 mM). In this study we demonstrated similar
benefits in protein degradation for much milder degrees of
acidosis. This suggests that even mild chronic acidosis is a
catabolic factor in CAPD.
In this study, we did not control for sodium ingestion using a
period of sodium chloride in equimolar amounts to the sodium
bicarbonate period. A previous study from this laboratory [1] has
shown that oral sodium loading with sodium chloride has no effect
on leucine kinetics.
An important part of this study has been the use of Kt/V urea
and NPCR in conjunction with three-day dietary recall to assess
protein and calorie intake throughout the study period. Changes
in dietary intake could produce similar results to that seen for the
correction of acidosis. In normal subjects decreasing protein
intake from 1.5 to 0.6 to 0.1 g kg' day' produces a fall in
post-absorptive PS from 125 3.7 to 107.4 2.2 to 84.5 5.3
.tmol kg1 day' [20]. For this reason it is important that protein
intake was consistent throughout the study period, since a fall in
dietary protein intake following the correction of acidosis could
theoretically have reduced PS. In the study there was no signifi-
cant change in protein intake as asssessed by dietary history
between the two study periods, in fact protein intake increased
from 66.6 4.9 (acid) to 74.6 6.9 (bicarbonate) g/24 hr,
although this increase was not statistically significant. yenning et
al [21] have suggested that Kt/V is mathematically and directly
related to PCR calculated from urea kinetics. Therefore, an
increase in Kt/V could lead to an increase in protein intake, at
Table 2. tCO2 before (acid) and after correction of acidosis (HCO3)
tCO2 mmol/liter pH
Subject Acid HCO3 Acid HCO3
Table 3. Glucose and intermediate metabolites
1 18.3 27.6 7.38 7.43
2 20.8 25.2 7.42 7.44
3 18.6 27.3 7.43 7.43
4 21.4 29.7 7.39 7.42
5 19.3 24.3 7.40 7.42
6 18.7 22.4 7.35 7.38
7 18.1 26.8 7.38 7.40
Acid Bicarbonate
Glucose, m,w 5.2 0.3 4.9 0.5
Pyruvate, fLM 62.7 12.5 58.3 9.5
Lactate, jiM 844 136 746 61
3-Hydroxybutyrate, pIe 53.4 21.8 59.0 32.6
Glycerol, pit 69.6 7.8 51.3 9.7
Values are means SE.
Statistical significance: tCO2, acid vs. HCO3, P < 0.001; pH, acid vs.
HCO3, P = 0.005.
Acid HCO3
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Taurine 39 5 42 7







least when calculated by urea kinetics, and this might also affect
PS and PD. However, no such changes were seen in this study.
Correction of acidosis in these subjects did not alter the
concentration of plasma amino acids, (with the exception of 3
methylhistidine, which fell significantly), this is consistent with the
study by Reaich et al [1]. If 3 methylhistidine is a valid marker for
skeletal muscle breakdown in humans [221, then it is not suprising
that the plasma concentration falls following the correction of
acidosis.
In contrast to some studies [1, 3] there was no change in leucine
oxidation following the correction of acidosis. An explanation for
this might be that CAPD has some effect on muscle branched
chain ketoacid dehydrogenase activity, which blunts the increased
activity seen in this enzyme in the rat model of acidosis [23]. it is
interesting that in a study of branched chain amino acid metabo-
lism conducted in chronic renal failure subjects and hemodialysis
subjects [24], leucine oxidation, although diminished in CRF (7.58
2.05) was no different in HD (13.16 2.3) when compared to
Kt/V NPCR
Subject Acid HCO1 Acid HCO3
1 2.76 2.55 1.57 1.28
2 1.11 0.96 0.67 0.61
3 2.28 2.43 1.3 1.25
4 2.85 2.34 1.16 1.24
5 1.38 1.26 0.84 0.83
6 2.43 2.37 0.73 0.73
7 2.46 2.34 0.54 0.62
Mean SE 2.18 0.25 2.03 0.24 0.97 0.14 0.93 0.12
Values for (NPCR) are given in g kg' day' actual body weight.
P values are: Kt/V urea, acid vs. HCO3, NS; NPCR, acid vs. HCO3, NS.
normal controls (12.42 3.29 mo11 kg1 hr1). Although the
acid-base status of the two groups was not stated in that study, it
is possible that leucine oxidation is also affected in a similar way
by CAPD.
In keeping with other studies there is a fall in plasma urea
following the correction of acidosis [18, 25], and this reflects the
reduction in protein degradation seen with the correction of
acidosis.
What is the mechanism for the acidosis induced catabolism in
CAPD? Animal studies suggest that acidosis activates the ATP-
dependent ubiquitin proteolytic pathway [26]. That a similar
mechanism is responsible in humans remains to be found. When
peritoneal dialysis solutions using lactate at a concentration of 35
mmol/liter are used, many patients have mild chronic metabolic
acidosis [6], and it has been reported that bicarbonate levels fall
with time on CAPD [27]. This negative buffer balance can be
corrected by increasing lactate concentration to 40 mmol/liter [6].
It is possible that peritoneal dialysis solutions using bicarbonate as
a buffer will improve acid-base homeostasis in CAPD, but the
optimal bicarbonate concentration has yet to be determined. Until
this has been done we would suggest that correction of acidosis
should be optimized by prescribing a dialysate containing 40
mmol/liter lactate for those patients whose tCO2 is consistently
below the normal range.
In conclusion, in CRF treated by CAPD the correction of
chronic metabolic acidosis decreases protein breakdown and
protein synthesis, but had no effect on leucine oxidation. These
findings confirm that metabolic acidosis is a catabolic stimulus in
PS
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Table 4. Leucine kinetics before and after the correction of acidosis
Subject Acid HCO, Acid HCO1
PD 0
Acid
1 195.4 137.2 192.3 132.1 3.1 5.0
2 176.3 139.7 166.7 131.4 9.6 8,3
3 220.0 136.4 200.5 127.1 19.4 9.3
4 202.9 158.3 194.6 150.3 8.1 8.0
5 201.2 145.0 193.1 134.9 8.1 10.1
6 255.5 154.6 239.0 133.8 15.9 20.2
7 230.7 125.2 218.5 117.5 12.2 7.8
HCO3
Mean SE 211.7 9.8 142.3 4.2 200.6 8.5 132.4 3.7 10.9 2 9.8 1.8
Values for leucine derived from protein degradation (PS), leucine incorporated into body protein via synthesis (PD) and leucine oxidation are given
in jimol kg1 hr1.
Statistical significance: PS, acid vs. bicarbonate, P < 0.001; PD, acid vs. bicarbonate, P < 0.001; 0, acid vs. bicarbonate, NS.
Table 5. Post-absorptive amino acid concentration (itmol/liter) Table 6. Weekly Kt/V urea and NPCR before and after the correction
of acidosis
Values are means SE.
Statistical significance for 3-methylhistidine, P < 0.05
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CAPD patients, and that correction of acidosis should be opti-
mized in patients undergoing treatment by CAPD.
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